ViewRay(OTC) VRAY

Market CapN/A

Since IPO (2015)-100%

5 Year-100%

1 Year+0%

1 Month+0%

N/A

ViewRay last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-10-09

ViewRay stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-10-01
1 month	+0%	USD 0.00	2026-09-08
3 month	+0%	USD 0.00	2026-07-09
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-10-07
3 year	-99.97%	USD 0.00	2023-10-10
5 year	-100%	USD 6.41	2021-10-08
Since inception	-100%	USD 5.00	2015-08-10

ViewRay Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$105.87M

Net Income (TTM)

-$114.17M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 8, 2024

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 8, 2024

VRAY News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ViewRay

ViewRay, Inc. is a medical device company specializing in innovative radiation therapy systems that integrate magnetic resonance imaging (MRI) technology. The company focuses on improving cancer treatment through its advanced MRIdian A3i system, which offers real-time tissue tracking and automated beam control.

Products and Services

MRIdian A3i: MRI-guided radiation therapy system
Real-time 3D tissue tracking for precise treatment
Applications for various cancers including prostate and breast

Growth Outlook

Recent bankruptcy filing may lead to restructuring opportunities
Potential for increased adoption of MRI-guided therapies in oncology
Focus on expanding international market presence for products

Financial Highlights

Q1 2023 revenue of $22.5 million, down from $34.7 million in Q4 2022
Net income for Q1 2023 was -$28.9 million, reflecting ongoing operational challenges
Cash and cash equivalents at $81.3 million as of March 31, 2023

ViewRay, Inc. has faced significant challenges, including a recent bankruptcy filing that transitioned from Chapter 11 to Chapter 7. This situation may present opportunities for restructuring and revitalization. The company's flagship product, the MRIdian A3i, is positioned in a growing market for MRI-guided radiation therapy, which is gaining traction among healthcare providers. Despite recent financial difficulties, the company maintains a substantial cash reserve, which may support future operations and strategic initiatives. Investors may find interest in the potential for recovery and growth in the oncology treatment landscape.

AI Generated • Sep 30, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

295

CEO

Scott William Drake

Website

www.viewray.com

Headquarters

Oakwood, OH 44146, US

VRAY Financials

Key Financial Metrics (TTM)

Gross Margin

9.83%

Operating Margin

-104.81%

Net Income Margin

-105.01%

Return on Equity

-85.17%

Return on Capital

-63.52%

Return on Assets

-39.55%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$8.52M

Operating Income

-$107.47M

EBITDA

-$99.16M

Operating Cash Flow

-$112.92M

Capital Expenditure

-$3.86M

Free Cash Flow

-$116.78M

Cash & ST Invst.

$81.29M

Total Debt

$85.13M

ViewRay Performance Analysis

ViewRay annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 70,119,000	N/A
2022	2022-12-31	USD 102,206,000	45.8%

ViewRay sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2022-06-30	17.3%
Q3	2022-09-30	19.6%
Q4	2022-12-31	31.0%
Q1	2023-03-31	-35.0%

ViewRay annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.67	N/A
2022	2022-12-31	USD -0.59	-11.2%

ViewRay sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2022-06-30	-15.4%
Q3	2022-09-30	-6.7%
Q4	2022-12-31	6.3%
Q1	2023-03-31	-13.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2023YOY CHG

Revenue

$22.53M

+19.4%

Gross Profit

-$1.43M

-1621.3%

Gross Margin

-6.35%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

295

N/A

Net Income

-$30.71M

-27.6%

EBITDA

-$25.27M

-7.7%

Quarterly Fundamentals

Name

Q1 2023YOY CHG

Total Cash

$81.29M

-54.9%

Total Debt

$85.13M

+26.4%

Accounts Receivable

$47.53M

+69.7%

Inventory

$42.19M

+61.8%

Long Term Debt

$4.44M

-92.2%

Short Term Debt

$80.69M

+654.9%

Return on Assets

-39.55%

N/A

Return on Invested Capital

-61.28%

N/A

Free Cash Flow

-$54.78M

-63.0%

Operating Cash Flow

-$53.60M

-65.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MDGSXylo Technologies Ltd.

MDGSXylo Technologies Ltd.$2.36+10.28%

NBRVFNabriva Therapeutics plc

NBRVFNabriva Therapeutics plc$0.00+0.00%

RHEPRegional Health Properties, Inc.

RHEPRegional Health Properties, Inc.$1.04+4.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CIFRCipher Digital

CIFRCipher Digital$11.34-12.77%

BMBLBumble

BMBLBumble$5.95+56.58%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$37.42+0.62%

INTCIntel

INTCIntel$102.81+1.44%

NVDANvidia

NVDANvidia$228.52+0.97%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$127.57-0.65%

NOKNokia

NOKNokia$9.86-0.40%

Questions About VRAY

What is the current price of ViewRay?

ViewRay is trading at N/A per share.

What is the 52-week range for ViewRay?

Over the past 52 weeks, ViewRay has traded between N/A and N/A.

How much debt does ViewRay have?

As of the most recent reporting period, ViewRay reported total debt of $86.40M.

How much cash does ViewRay have on hand?

ViewRay reported $135.96M in cash and cash equivalents in its most recent financial results.

What is ViewRay’s dividend yield?

ViewRay does not currently have a dividend yield.

ViewRay(OTC) VRAY

ViewRay Financials at a Glance

VRAY News

Why ViewRay Stock Is Sinking Today

Why ViewRay Crushed the Market on Thursday

Why ViewRay Stock Vaulted Higher Today

Why ViewRay Stock Got Crushed Today

Why ViewRay Stock Dropped Today

Why ViewRay Stock Is Tanking Today

Why Lands' End, Audentes Therapeutics, and ViewRay Jumped Today

Why ViewRay Stock Is Shooting Higher Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ViewRay

VRAY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ViewRay Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VRAY

What is the current price of ViewRay?

What is the 52-week range for ViewRay?

How much debt does ViewRay have?

How much cash does ViewRay have on hand?

What is ViewRay’s dividend yield?

Premium Investing Services